In Vivo, Non-Invasive Drug Discovery and Development

Small animal models are now an integral part of pharmaceutical drug discovery and development prior to commercialization. Small animal imaging is an efficient and cost-effective research platform for the timely validation and commercialization of novel drug agents. These technologies are essential to developing an understanding of the underlying mechanisms of conditions such as cancer, diabetes, and cardiovascular, immunological and neurodegenerative diseases.¹

In vivo small animal imaging allows researchers to noninvasively screen, analyze and monitor animal models before, during and after experimental intervention or drug administration, resulting in quantitative measurements of study outcomes. Small animal imaging generates more relevant, translatable data from drug discovery and development studies than ex vivo techniques. See how our Vevo imaging systems fit into the drug discovery process below:

Explore the possibilities in:

• Biomarker research & investigation
• Interventional procedures
• High-throughput screening in real-time
• Toxicology studies
• Understanding disease onset & progression

Benefits:

• Pre-safety assessment of drug liability
• De-risking of potential therapeutics compounds
• Development of non invasive biomarkers of efficacy and/or injury of drugs
• Turn key imaging protocols to visualize structural, functional or molecular biomarkers in               research areas including Cardiovascular, Cancer, Reproductive and more
• Data management - data captured from studies can be managed using VisualSonics iPACS solution

 
About VisualSonics iPACS:

1 Applied Clinical Trials: http://www.appliedclinicaltrialsonline.com/small-animal-imaging-develops-role-drug-development